ホーム>>Signaling Pathways>> Toxins>> Mycotoxins>>(-)-Viriditoxin

(-)-Viriditoxin

カタログ番号GC45253

(-)-ビリディトキシンは、元々Aから分離されたマイコトキシンです。

Products are for research use only. Not for human use. We do not sell to patients.

(-)-Viriditoxin 化学構造

Cas No.: 1381782-08-6

サイズ 価格 在庫数 個数
500μg
$221.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Background

(-)-Viriditoxinは、元々A. viridinutansから分離されたマイコトキシンであり、抗菌および抗増殖活性を持っています。メチシリン感受性および耐性のS. aureus(それぞれMSSAおよびMRSA)、テトラサイクリン感受性および耐性のStaphylococcus、バンコマイシン感受性および耐性のEnterococcus、ペニシリン感受性および耐性のS. pneumoniaeに対して有効です(MICs = 2-32 μg/ml)。(-)-Viriditoxinはまた、S. iniaeやS. parauberisなどの魚病原体にも有効です(MICs = 0.16-0.21 μg/ml)。これは細菌細胞分裂に関与するチューブリン様GTPaseであるE.coli FtsZの重合とGTPase活性を阻害します(IC50s = 8.2および7μg/ml)。(-)-Viriditoxinは人間の前立腺がん細胞DU145、LNCaP、PC3の増殖を阻害します(IC50s=5,36,0,63,7,6μM)。また、マウスに対しても毒性があります(LD50=2.8mg/kg、i.p.)。

Chemical Properties

Cas No. 1381782-08-6 SDF
Canonical SMILES OC1=CC(OC)=[C@]([C@]2=C(OC)C=C(O)C3=C2C=C(C[C@@H](CC(OC)=O)OC4=O)C4=C3O)C5=C1C(O)=C6C(C[C@@H](CC(OC)=O)OC6=O)=C5
Formula C34H30O14 M.Wt 662.6
溶解度 DMSO: soluble,Ethanol: soluble Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 1.5092 mL 7.546 mL 15.0921 mL
5 mM 0.3018 mL 1.5092 mL 3.0184 mL
10 mM 0.1509 mL 0.7546 mL 1.5092 mL
  • モルアリティ計算機

  • 希釈計算機

質量
=
濃度
x
容積
x
MW*
 
 
 
**ストックソリューションを準備する際には、常にバイアルラベルおよび MSDS/CoA(オンラインで利用可能)で掲載された製品のロット固有分子量を使用してください。

計算

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

レビュー

Review for (-)-Viriditoxin

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (-)-Viriditoxin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.